LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.
The Valeda system has received a CE mark in Europe for the treatment of ocular diseases including dry age-related macular degeneration. The new studies in diabetic retinopathy will take place with the University of Wisconsin-Milwaukee.
“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with
Uncategorized